

DAMAGE TO THE CENTRAL NERVOUS SYSTEM IN COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN

I.A.Karimdzhанov¹  M.K Togaev¹  A.S.Gazieva¹ 

1. Tashkent Medical Academy, Tashkent, Uzbekistan.

Abstract.

Relevance. Community-acquired pneumonia (CAP) with complications is typical for respiratory diseases and occurs in up to 20% of children. In addition to respiratory failure, children with CAP often experience complications from the central nervous system (CNS). Such complications include toxic-metabolic syndrome, convulsive syndrome, hypoxic encephalopathy. **Purpose of the study.** Early diagnosis, prevention of complications and optimization of treatment of children with CAP with central nervous system and heart damage. **Methods and research.** Under observation were 48 children with CAP who were being treated at a multidisciplinary clinic of the Tashkent Medical Academy; 14 (29.16%) children had toxic-metabolic syndrome, 12 (25.00%) had pathological changes in the cardiovascular system. The levels of respiratory failure and saturation indicator were determined, an ultrasound examination of the brain, an ECG and general clinical and laboratory tests were performed. **Research results.** In 15 (31.25%) sick children, a severe course of VP, symptoms of III degree DN, saturation index $\leq 85.0\%$, 16.6% signs of hypoxia during an UTT study of the brain were revealed. 14 (29.16%) treated children had symptoms of damage to the nervous system 18 (37.5%), had pathological changes in the cardiovascular system 17 (35.41%) (decrease in the QRS complex 15 (31.25%), partial block of the right branch of the His bundle 7 (14.58%) and 4 (8.33%) had a partial block of the left branch of the bundle Gissa. **Conclusions.** To optimize the early diagnosis and treatment of the acute phase of CAP, central nervous system and heart damage, it is necessary to conduct symptomatology of DN, radiography, ultrasonography, MSCT and ECG of the lungs, determine and correct the O₂ saturation index, and consult a pediatric neurologist and cardiologist.

Key words: community-acquired pneumonia, children, central nervous system damage, hospital treatment, oxygen therapy.

Bolalarni shifoxona sharoitida davolanishga olib keluvchi kasalliklar ichida nafas tizimi kasalliklari birinchi o'ringda turadi. Nafas tizimi kasalliklaridan shifoxonadan tashqari pnevmoniya (ShTP) asoratlar bilan kechish xos bulib bolalar orasida 20%gacha uchraydi. Bundan tashqari ShTP bolalarda o'limga olib keluvchi asosiy sabablardan biri xisoblanadi, va kasallikni erta tashxislash va samarali davolash muximligini tasdiqlaydi. [1, 2, 4].

ShTP bilan og'riq bolalarda nafas yetishmovchiligidan tashqari, markaziy asab tizimida (MAT) aniqlanadigan asoratlar ham tez-tez kuzatilib turadi. Bu asoratlar: toksik – metabolik sindrom, talvasa sindromi, gipoksik ensefalopatiyalar kabidir. Bu asoratlarni ShTPda uchrashi bolalarni shifoxona sharoitida uzoq vaqt davomida davolanishiga olib keladi va bolalarning xayot sifatiga salbiy ta'sir ko'rsatadi. [3, 5, 6].

ShTP (J18.0) – o'pkaning o'tkir nospetsifik infeksiya yallig'lanish kasalligi hisoblanib, respirator bo'limning o'choqli zararlanishi hamda alveolar ichiga ekssudat yig'ilishi bilan kechadi. Kasallik chaqiruvchilari ko'p hollarda turli xil bakteriyalar, viruslar va kam hollarda zamburug'lar hisoblanadi. Qo'shma virusli va bakterial qo'zg'atuvchilar tomonidan xam ShTPlar chaqiriladi [7, 8, 11b 12].

Turli yoshdagi bolalarda ShTP o'z kechish xususiyatlariga ega. Erta yoshdagi bolalarda ShTP etiologiyasida ko'proq *Str.pneumoniae* uchrasa, kichik va katta yoshdagi bolalarda *Str.pneumoniae* bilan birga mikoplazma, xlamidiyalar xam uchraydi. Bolalar orasida ShTP asosan 5 yoshgacha bo'lgan davrda ko'proq uchraydi, va bu xolatlarda kasallikni asoratlar bilan og'ir kechishi kuzatiladi

[7, 8, 9]. ShTPni davolashda keng antibakterial preparatlardan foydalaniladi, jumladan amoksitsillin, amoksitsillin klavulanat, makrolidlar, sefalosporinlar va xok.. Asoratsiz kechadigan ShTPda antibakterial preparatlar og‘iz orqali qabul qilinadi. Og‘ir kechadigan ShTPda antibiotiklar parenteral ravishda qo‘llaniladi va bemorni axvoli yaxshilanganidan keyin qadamma-qadam og‘iz orqali qabulga o‘tiladi [8, 9, 10].

Oxirgi yillarda ShTPning asoratlangan turlari ko‘payib borishini inobatga olib va davolash samarasini oshirish yo‘llarini izlab mazkur ilmiy tadqiqot ishini maqsad kilib qo‘ydik.

Tekshiruv maqsadi.

ShTPni bolalarda MAT va yurak zararlanishi bilan kechganda erta tashxislash, asoratlarni oldini olish va davolashni optimallashtirishdan iborat

Tekshiruv ob‘ekti va usullari.

Tekshiruvlar Toshkent tibbiyot akademiyasining ko‘p tarmoqli klinikasining bolalar bo‘limida olib borildi. Qo‘yilgan maqsad va vazifalarni bajarish uchun ShTP tashxisi qo‘yilgan va shifoxonada davolanayotgan 1-3 yoshli 48 nafar bemor bolalar kuzatuvga olindi. Pnevmoniya tashxisi anamnestik, klinik, fizikal tekshiruvlar (palpatsiya, perkussiya, auskultatsiya), instrumental (o‘pka UTT, ko‘krak qafasi rentgenogrammasi, ko‘krak qafasi MSKT/KT, saturatsiya ko‘rsatkichi, EKG, miya UTT), laborator tekshiruvlar (umumiy qon, qon bioximik tahlili, peshob va axlat tahlili) ko‘rsatkichlari natijalari asosida, 10 Xalqaro Kasalliklar Tasnifi va Geppe N.A. va xamm., (2010) tavsiyalari bo‘yicha qo‘yildi. Bemorlarni davolashda standart davolash usullaridan foydalanilgan holda antibiotikaterapiya, oksigenoterapiya, vitaminoterapiya va simptomatik terapiya olib borildi.


Natijalar.

Kasallik klinikasi o‘rganilganda - bemorlarda yo‘tal 48 (100%), hansirash 35(72,91%), akrotsianoz 20 (41,66%), isitma 40 (83,33%), taxikardiya 15 (31,25%), saturatsiya ko‘rsatkichining pasayishi 38 (79,16%), injiqlik 18 (37,5%), uyquning buzilishi 17 (35,41%), rentgenografik tekshiruvlarda o‘pka to‘qimasida soyalanishlar 48 (100%) aniqlandi. Laborator tekshiruvlardan leykotsitoz 16(33,33%) nafar bolalarda kuzatilgan, limfotsitoz 12(25,0%) nafar bolalarda, S-reaktiv oqsil 25(56,25%) nafar bolalarda yuqori bo‘lgan, va umumiy oqsil 23(47,91%) nafar bolalarda referent ko‘rsatkichlardan kam bo‘lganligi aniqlangan.

Kuzatilgan bemorlarning 14 (29,16%) nafarida MAT zararlanishi toksik – metabolik sindrom ko‘rinishida kuzatildi. Toksik – metabolik sindrom belgilari: umumiy holsizlik, kuchli bezovtalik, uyquning buzilishi, injiqlik, ishtaxasizlik, va boshqalar kiradi. Toksik – metabolik sindrom kuzatilgan bemorlarga antibiotik bilan terapiyaga qo‘shimcha ravishda dezintkatsion davo o‘tkazildi.

Diagramma-1

ShTP bilan kasallangan bemor bolalarda asoratlarni uchrashi



Bemorlarning 15 (31,25%) nafarda og‘ir axvol kuzatildi, shu bemorlar klinik ko‘rsatmaga binoan reanimatsiya bo‘lmiga o‘tqazildi. Reanimatsiyaga o‘tqazilgan bemorlarning 8 (16,66%) nafarida III

darajali nafas yetishmovchiligi kuzatildi. Kasallik og'ir shaklda kechganida, kuzatilgan bemorlarning 38 (79,16%) nafarida saturatsiya ko'rsatkichi 90% dan past bo'ldi, reanimatsiya bo'limiga o'tqazilgan bemorlarda saturatsiya ko'rsatkichi 85%dan kam bo'ldi, mos ravishda bu bemorlarda II - III darajali nafas yetishmovchiliklari aniqlandi. Toksik – metabolik sindrom ko'rinishda MAT zararlanishi kuzatilgan bemorlarning 8(16,66%) nafarida neyrosonografiyada gipoksiya belgilari aniqlandi.

Bolalarning jonlantirish va intensiv davolash bo'limlarida davolangan 15(31,25%) nafar bemorlarda EKG tekshiruvi o'tkazilganida barcha bemorlarda QRS kompleksining pasayishi, 7(14,58%) nafarida Giss tutami o'ng oyog'i, 4(8,33%) nafarida Giss tutami chap oyog'i qisman blokadasi kuzatildi. Kasallik toksik-metabolik sindrom va yurakdagi o'zgarishlar bilan xamroxlikda kechganida, asoratlar kuzatilmagan guruxga nisbatan og'irroq kechdi.

Davolash muddatlari asoratlanmagan ShTPda 5-7 kun davom etgan bo'lsa, asoratlangan ShTPda 8-10 kunni tashkil qildi.

Xulosa.

1. ShTPda toksik – metabolik sindrom 14(29,16%) bolalarda uchrashi aniqlandi.
2. Bemor bolalarning 15 (31,25%) nafarida ShTPning og'ir kechishi aniqlanib (III darajali Ne belgilari, saturatsiya ko'rsatkichi $\leq 85,0\%$, bosh miyada UTT tekshiruvida 16,6% gipoksiya belgilari) ular jonlantirish bo'limida davolandi.
3. Jonlantirish va intensiv davolash bo'limda davolangan bemor bolalarda yurak qon – tomir tizimi tomonidan patologik o'zgarishlar aniqlandi(QRS kompleksining pasayishi 15(31,25%), Giss tutamining o'ng oyoqchasi 7(14,58%) va chap oyoqchasi 4(8,33%) nafarida qisman blokadasi kuzatildi. Bu o'zgarishlar pnevmoniyaning asoratlanmagan shakli bilan og'irigan bemorlarda kuzatilmadi.
4. ShTP davolashni optimallashtirish uchun kasallik asoratlar bilan kechishi jarayonida tor mutuxassislardan bolalar nevropatologi va kardiologi maslaxatlarini, o'pkaning rentgen, UTT, MSKT hamda EKG larni o'tkazish, oksigenoterapiyalardan foydalanish lozim.
5. Bolalarda ShTPda MAT va yurak shikastlanganida shifoxonada davolanish muddati 2-3 kunga uzayadi va bu davolashni o'z vaktida korreksiya qilishni taqozo etadi.

List of references

- [1] Meyer Sauter PM, Beeton ML, on behalf of the ESGMAC and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. *Lancet Microbe*. 2023;23:S2666-5247(2623)00344 00340. doi: 10.1016/S2666-5247(23)00344-0.
- [2] Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. *Korean Journal of Pediatrics* 2012; 55(2):42-7. <https://doi.org/10.3345/kjp.2012.55.2.42>
- [3] Karimdzhanov I.A., Madaminova M.Sh., Iskanova G.Kh., Gazieva A.S., Togaev M.Q. Diagnosis and treatment of community-acquired pneumonia in children. *Child health*, 2024, T.19, N5, 2024, p.65-68
- [4] Danino D, Ben-Shimol S, Van Der Beek BA, Givon-Lavi N, Avni YS, et al. Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel as associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study. *Clin Infect Dis*. 2022;75:e1154-e1164. doi: 10.1093/cid/ciab1014
- [5] Karimdzhanov IA, Iskanova GK, Isroilova NA. Sequential therapy of community-acquired pneumonia in children. *Child's Health*. 2014;3(54):70-73. doi: 10.22141/2224-0551.3.54.2014.76003.
- [6] Bielicki JA, Stohr W, Barratt S, Dunn D, Naufal N, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. *JAMA*. 2021;326:1713-1724. doi: 10.1001/jama.2021.17843.
- [7] Kuitunen I, Jaaskelainen J, Korppi M, Renko M. Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries — a systematic review and meta-analysis. *Clin Infect Dis*. 2023;76:e1123-e1128. doi: 10.1093/cid/ciac374.
- [8] Furman E.G., Balkunova Yu.N., Boyko M.Yu., Estemesova R.A. Ultrasound examination of the

lungs in the diagnosis of pneumonia in children. Doctor.Ru. 2024;23(6):58–63. DOI: 10.31550/1727-2378-2024-23-6-58-63

[9] Huang W, Xu X, Zhao W, Cheng Q. Refractory Mycoplasma pneumoniae in Children: A Systematic Review and Meta-analysis of Laboratory Features and Predictors. J Immunol Res. 2022 Jun 26;2022:9227838. doi: 10.1155/2022/9227838.